Date Name Title Filing Type Shares Traded Price Total Held
Feb 03, 2006
SVP, PreclinDevel & Biomol Sci
SVP, PreclinDevel & Biomol Sci Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 24,000 $7.41 27,127
Feb 03, 2006
SVP, PreclinDevel & Biomol Sci
SVP, PreclinDevel & Biomol Sci Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 24,000 -- --
Oct 31, 2006
SVP, Therap & Clin Prog Dev
SVP, Therap & Clin Prog Dev Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 24,226 $10.56 33,873
Oct 31, 2006
SVP, Therap & Clin Prog Dev
SVP, Therap & Clin Prog Dev Form 4 Open market or private sale of non-derivative or derivative security 24,226 $20.00 9,647
Oct 31, 2006
SVP, Therap & Clin Prog Dev
SVP, Therap & Clin Prog Dev Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 24,226 -- 7,463
Dec 11, 2019
EVP Research and Development
EVP Research and Development Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 24,500 -- 24,500
Jul 27, 2009
SVP Res and Dev Sciences
SVP Res and Dev Sciences Form 4 Open market or private sale of non-derivative or derivative security 24,686 $20.74 2,550
Jun 19, 2012
SVP Res & Dev Sciences
SVP Res & Dev Sciences Form 4 Open market or private sale of non-derivative or derivative security 24,848 $115.60 73,184
Feb 26, 2020
EVP Research and Development
EVP Research and Development Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 25,000 -- 38,079
Feb 26, 2020
EVP Research and Development
EVP Research and Development Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 25,000 $52.03 36,380

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.